The life expectancy of standard-risk myeloma patients has increased significantly in the last decade, thanks to novel therapies. Some trials that are in progress, such as the MAIA trial comparing Revilmid and dexamethasone (Rd) versus Daratumumab, Revilmid and dexamethasone (DRd) have not yet met their progression-free survival (PFS) end state and are at more than […]